<DOC>
	<DOCNO>NCT00275080</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat give together decitabine treat patient advance solid tumor relapse refractory non-Hodgkin 's lymphoma , acute myeloid leukemia , acute lymphocytic leukemia , chronic myelogenous leukemia . Vorinostat may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , decitabine , work different way stop growth cancer cell , either kill cell stop divide . Giving vorinostat together decitabine may kill cancer cell .</brief_summary>
	<brief_title>Vorinostat Decitabine Treating Patients With Advanced Solid Tumors Relapsed Refractory Non-Hodgkin 's Lymphoma , Acute Myeloid Leukemia , Acute Lymphocytic Leukemia , Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Establish maximum tolerate dose recommended phase II dose vorinostat conjunction decitabine patient advance solid tumor relapse refractory non-Hodgkin 's lymphoma , acute myeloid leukemia , acute lymphocytic leukemia , chronic myelogenous leukemia blast crisis . SECONDARY OBJECTIVES : I . Identify minimal effective dose vorinostat conjunction decitabine lead DNA demethylation , histone acetylation , gene reactivation tolerable toxicity patient . II . Determine pharmacokinetic profile vorinostat decitabine patient . Correlate pharmacokinetic profile vorinostat decitabine toxicity biological activity patient . III . Assess antitumor activity vorinostat decitabine patient . OUTLINE : This parallel group , multicenter , dose-escalation study vorinostat . Patients stratify accord disease ( solid tumor non-Hodgkin 's lymphoma [ NHL ] v hematological malignancy ) . Patients receive 1 2 dosing regimen . Regimen 1 ( sequential dosing ) : Patients receive oral vorinostat two three time daily day 6-21 day 6-12 ( patient solid tumor NHL ) decitabine IV 1 hour day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Regimen 2 ( concurrent dose ) : Patients receive oral vorinostat two three time daily day 1-21 , day 1-14 ( patient hematological malignancy ) , two time daily day 1-12 ( patient solid tumor NHL ) decitabine IV 1 hour day 1-5 . Courses repeat every 28 day 21 day ( patient hematological malignancy ) absence disease progression unacceptable toxicity . In group , cohort 3-6 patient receive escalate dos vorinostat maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . The dose level MTD would declare recommended phase II dose ( RPTD ) . Up 10 patient treated RPTD . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Diagnosis 1 follow : Confirmed relapsed refractory acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) chronic myelogenous leukemia blast crisis ( CMLBC ) Patients acute promyelocytic leukemia relapse tretinoin allow Patients previously untreated AML refuse induction chemotherapy allow Patients candidate aggressive management ( medical condition prevent administration standard curative chemotherapy require allogeneic bone marrow transplantation curative therapy lack appropriate donor ) allow Histologically cytologically confirm relapsed refractory nonHodgkin 's lymphoma ( NHL ) Histologically confirm solid tumor metastatic unresectable standard curative palliative measure exist longer effective Clinically radiologically document disease Patients whose evidence disease tumor marker elevation eligible Patients AML , ALL , CMLBC cerebral spinal fluid involvement may include May treat intrathecal cytarabine and/or methotrexate prior and/or study No known brain metastasis patient solid tumor NHL ECOG performance status 02 Karnofsky 60100 % Life expectancy &gt; 12 week patient solid tumor ( include nonHodgkin 's lymphoma ) 6 week patient hematological malignancy Patients solid tumor ( include NHL ) must also normal marrow function define : Leukocytes ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelets ≥ 100,000/mm^3 Creatinine ≤ 150 μmol/L Creatinine clearance ≥ 60 mL/min Bilirubin normal AST/ALT ≤ 2.5 time upper limit normal ( ULN ) Women childbearing potential men must agree use adequate contraception ( barrier method birth control abstinence ) prior study entry duration study participation Not pregnant nursing Negative pregnancy test No history allergic reaction attribute compound similar chemical biologic composition vorinostat agent use study Able take oral medication Patients clinical radiological diagnosis bowel obstruction ineligible No ongoing active infection No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No psychiatric illness/social situation would limit compliance study requirement No uncontrolled intercurrent illness No limitation number type prior therapy At least 3 week since prior radiotherapy , chemotherapy ( 6 week nitrosoureas mitomycin C ) , molecularly target agent Exceptions may make lowdose , nonmyelosuppressive radiotherapy At least 2 week since prior valproic acid histone deacetylase inhibitor Must recover prior therapy Patients hematological malignancy may receive hydroxyurea 24 hour prior start study medication Previous surgery permit provide wound heal occur No prior decitabine No concurrent investigational agent No concurrent investigational commercial agent therapy administer intent treat patient 's malignancy No HIVpositive patient receive combination antiretroviral therapy No concurrent prophylactic hematopoietic growth factor ( e.g . filgrastim [ GCSF ] , sargramostim [ GMCSF ] , thrombopoietin , epoetin alfa ) Hematopoietic growth factor colony stimulate factor treatment cytopenia may permit discretion principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>